摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 2-azabicyclo[2.2.2]octane-6-carboxylate | 122684-56-4

中文名称
——
中文别名
——
英文名称
methyl 2-azabicyclo[2.2.2]octane-6-carboxylate
英文别名
6-carbomethoxy-2azabicyclo[2.2.2]octane;endo-6-carbomethoxy-2-azabicyclo[2.2.2]octane
methyl 2-azabicyclo[2.2.2]octane-6-carboxylate化学式
CAS
122684-56-4
化学式
C9H15NO2
mdl
——
分子量
169.224
InChiKey
ZIUUUKKAMFKVCY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.89
  • 拓扑面积:
    38.3
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    methyl 2-azabicyclo[2.2.2]octane-6-carboxylate二碳酸二叔丁酯二氯甲烷 为溶剂, 生成 2-tert-butyl 6-methyl (1R*,4S*)-2-azabicyclo[2.2.2]octane-2,6-dicarboxylate
    参考文献:
    名称:
    Lipophilic oxadiazoles
    摘要:
    式I中的氧代唑,其中X、Y和Z中的一个是氧原子,另外两个是氮原子,虚线圈代表芳香性(两个双键),从而形成1,3,4-氧代唑或1,2,4-氧代唑核;R¹代表非芳香性的杂环或氮杂双环环系统;R²代表至少有三个碳原子的可选择取代的饱和碳氢基团,或至少有6个碳原子的不饱和碳氢基团,对于治疗和/或预防神经退行性疾病具有特别有利的选择性特性。
    公开号:
    EP0323864A3
点击查看最新优质反应信息

文献信息

  • Physiologically active 1,2,4,-oxa- and thiadiazoles
    申请人:Merck Sharp & Dohme Ltd.
    公开号:US04952587A1
    公开(公告)日:1990-08-28
    The present invention provides a compound of formula I or a salt or prodrug thereof: ##STR1## wherein the dotted circle represents one or two double bonds in any position in the 5-membered ring; X, Y and Z independently represent oxygen, sulphur, nitrogen or carbon, provided that at least one of X, Y and Z represents oxygen, sulphur or nitrogen; A represents a group of formula II: ##STR2## in which R.sup.1 represents hydrogen, hydroxy, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 alkoxy, hydroxy(C.sub.1-6)alkyl, halogen, amino, cyano, --CONR.sup.6 R.sup.7 or --SO.sub.2 NR.sup.6 R.sup.7, in which R.sup.6 and R.sup.7 independently represent hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; R.sup.2 represents hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or C.sub.1-6 alkylcarbonyl; V represents nitrogen, ##STR3## and W represents oxygen, sulphur or ##STR4## in which R.sup.8 represents hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; E represents a bond or a straight or branched alkylene chain containing from 1 to 5 carbon atoms, and optionally being substituted with hydroxy or phenyl; and F represents: (a) a non-aromatic azacyclic or azabicyclic ring system; or (b) a group of formula --NR.sup.a R.sup.b, in which R.sup.a and R.sup.b independently represent hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl or aryl(C.sub.1-6)alkyl; which compounds are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal; pain; gastric stasis; gastric dysfunction (such as occurs with dyspepsia, peptic ulcer, reflux oesophagitis and flatulence); migraine, nausea and vomiting; and presenile and senile dementia.
    本发明提供一种式I的化合物或其盐或前药:##STR1## 其中虚线圆圈表示5元环中任何位置的一个或两个双键;X、Y和Z独立地表示氧、硫、氮或碳,但至少其中之一表示氧、硫或氮;A表示式II的基团:##STR2## 其中R.sup.1表示氢、羟基、C.sub.1-6烷基、C.sub.2-6烯基、C.sub.2-6炔基、C.sub.1-6烷氧基、羟基(C.sub.1-6)烷基、卤素、氨基、氰基、--CONR.sup.6R.sup.7或--SO.sub.2NR.sup.6R.sup.7,其中R.sup.6和R.sup.7独立地表示氢、C.sub.1-6烷基、C.sub.2-6烯基或C.sub.2-6炔基;R.sup.2表示氢、卤素、C.sub.1-6烷基、C.sub.1-6烷氧基或C.sub.1-6烷基羰基;V表示氮、##STR3## 且W表示氧、硫或##STR4## 其中R.sup.8表示氢、C.sub.1-6烷基、C.sub.2-6烯基或C.sub.2-6炔基;E表示一条含有1至5个碳原子的直链或支链烷基链,可选地被羟基或苯基取代;F表示:(a)非芳香族的氮杂环或氮杂双环环系;或(b)式--NR.sup.aR.sup.b的基团,其中R.sup.a和R.sup.b独立地表示氢、C.sub.1-6烷基、C.sub.2-6烯基、C.sub.2-6炔基或芳基(C.sub.1-6)烷基;这些化合物在治疗精神障碍(如精神分裂症和躁狂)、焦虑、酒精或药物戒断、疼痛、胃潴留、胃功能障碍(如消化不良、消化性溃疡、反流性食管炎和胃胀气)、偏头痛、恶心和呕吐以及老年性痴呆症方面具有用途。
  • 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE
    申请人:Nagase Tsuyoshi
    公开号:US20120232109A1
    公开(公告)日:2012-09-13
    [Problem] There is provided a compound useful as a preventive or remedy for cardiovascular disease, neurologic disease, metabolic disease, reproductive disease, and digestive disease. [Means for Resolution] A compound or a pharmaceutically acceptable salt thereof represented by the following Formula (I) wherein Z represents wherein n1, n2, and n3 are 0, 1, or 2, respectively; R 1 represents C 1-6 alkyl, C 3-8 cycloalkyl, or the like; R 2 represents aryl or heteroaryl; R 3 represents a hydrogen atom, C 1-6 alkyl, or the like; and M 1 , M 2 , M 3 , and M 4 independently represent a hydrogen atom, C 1-6 alkyl, or the like, or M 1 , together with M 2 , M 3 , or M 4 , forms —CH 2 — or the like.
    [问题] 提供了一种化合物,可用作预防或治疗心血管疾病、神经疾病、代谢性疾病、生殖疾病和消化疾病的药物。[解决方法] 化合物或其药学上可接受的盐,由以下式(I)所表示的化合物其中Z表示其中n1、n2和n3分别为0、1或2;R1表示C1-6烷基、C3-8环烷基或类似物;R2表示芳基或杂环芳基;R3表示氢原子、C1-6烷基或类似物;M1、M2、M3和M4分别独立地表示氢原子、C1-6烷基或类似物,或M1与M2、M3或M4一起形成-CH2-或类似物。
  • Pyrazines, pyrimidines and pyridazines, useful in the treatment of senile dementia
    申请人:MERCK SHARP & DOHME LTD.
    公开号:EP0327155A2
    公开(公告)日:1989-08-09
    The present invention provides pyrazines, pyridazines or pyrimidines, or salts or prodrugs thereof, substituted on one of the ring carbon atoms therefore with a non-aromatic azacyclic or azabicyclic ring system; and independently substituted on each of the other ring carbon atoms with a substituent of low lipophilicity or a hydrocarbon substituent; which compounds stimulate central muscarinic acetylcholine receptors and therefore are useful in the treatment of neurological and mental illnesses.
    本发明提供吡嗪类、哒嗪类或嘧啶类化合物,或其盐类或原药,其中一个环碳原子被非芳族氮杂环或氮杂环环系取代;其他每个环碳原子分别独立地被低亲脂性取代基或烃类取代基取代;这些化合物可刺激中枢毒蕈碱乙酰胆碱受体,因此可用于治疗神经和精神疾病。
  • Five-membered ring systems with bonded azacyclic ring substituents
    申请人:MERCK SHARP & DOHME LTD.
    公开号:EP0328200A1
    公开(公告)日:1989-08-16
    The present invention provides a compound of formula I or a salt or prodrug thereof: wherein the dotted circle represents one or two double bonds in any position in the 5-membered ring; X, Y and Z independently represent oxygen, sulphur, nitrogen or carbon, provided that at least one of X, Y and Z represents oxygen, sulphur or nitrogen; A represents a group of formula II: in which: R' represents hydrogen, hydroxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, hydroxy(C1-6)alkyl, halogen, amino, cyano, -CONR6R7 or -S02NR6R7, in which R6 and R7 independently represent hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl; R2 represents hydrogen, halogen, C1 -6 alkyl, C1 -s alkoxy or C1 -6 alkylcarbonyl; V represents nitrogen, - CH or - C -; and W represents oxygen, sulphur or - NR8, in which R8 represents hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl; E represents a bond or a straight or branched alkylene chain containing from 1 to 5 carbon atoms, and optionally being substituted with hydroxy or phenyl; and F represents: . a) a non-aromatic azacyclic or azabicyclic ring system; or b) a group of formula -NRaRb, in which Ra and Rb independently represent hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-s alkynyl or aryl(C1-6)alkyl; which compounds are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal; pain; gastric stasis; gastric dysfunction (such as occurs with dyspepsia, peptic ulcer, reflux oesophagitis and flatulence); migraine, nausea and vomiting; and presenile and senile dementia.
    本发明提供了式 I 的化合物或其盐或原药: 其中圆点代表五元环任意位置上的一个或两个双键; X、Y和Z独立地代表氧、硫、氮或碳,条件是X、Y和Z中至少有一个代表氧、硫或氮; 其中 R'代表氢、羟基、C1-6 烷基、C2-6 烯基、C2-6 炔基、C1-6 烷氧基、羟基(C1-6)烷基、卤素、氨基、氰基、-CONR6R7 或 -S02NR6R7,其中 R6 和 R7 独立地代表氢、C1-6 烷基、C2-6 烯基或 C2-6 烷炔基; R2 代表氢、卤素、C1-6 烷基、C1-s 烷氧基或 C1-6 烷基羰基; V 代表氮、- CH 或 - C -;以及 W 代表氧、硫或- NR8,其中 R8 代表氢、C1-6 烷基、C2-6 烯基或 C2-6 烷炔基; E 代表键或含有 1 至 5 个碳原子的直链或支链亚烷基链,可选择被羟基或苯基取代; 以及 F 代表 a) 非芳氮杂环或氮杂环环系;或 b) 式-NRaRb 的基团,其中 Ra 和 Rb 独立代表氢、C1-6 烷基、C2-6 烯基、C2-s 烷炔基或芳基(C1-6)烷基。这些化合物可用于治疗精神病(如精神分裂症和躁狂症)、焦虑、戒酒或戒毒、疼痛、胃淤血、胃功能障碍(如消化不良、消化性溃疡、反流性食道炎和胀气)、偏头痛、恶心和呕吐以及先天性和老年性痴呆。
  • 3-SUBSTITUTED SULFONYL PIPERAZINE DERIVATIVE
    申请人:MSD K.K.
    公开号:EP2261210B1
    公开(公告)日:2014-10-22
查看更多